AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback